]>

IRCT20210730052015N1 IRCT 2021-09-25 Arak University of Medical Sciences Comparison of the effectiveness of treatment of iron deficiency anemia with daily vs. every other day oral iron supplementation Comparison of the effectiveness of treatment of iron deficiency anemia with daily vs. every other day oral iron supplementation 2021-09-21 anticipated 376 Complete https://irct.ir/trial/58507 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, randomized block method was used for randomization. For this purpose, a block of 4 is used. In such a way that first 4 blocks are prepared as BAAB, BABA, BBAA, AABB, ABAB, ABB and then these blocks are arranged randomly and people are assigned to two groups according to A or B and this work is continuous. Will be repeated to reach the desired sample size, Blinding description: The study is one-sided blind, which means that none of the participants is aware of how individuals are assigned to the groups. Labels A and B are labeled on the packages, but only the researcher knows the true nature of the supplements. 3 Iron deficiency anemia. Intervention 1: Intervention group: In one group of patients, 150-200 mg of elemental iron is given daily (in the form of ferrofort tablets of Abidi Pharmaceutical Company twice a day). Intervention 2: Intervention group: In the second group, patients are treated every other daybetween 150-200 mg of elemental iron (in the form of ferrufort tablets of Abidi company twice a day every other day). Yes - There is a plan to make this available What will be shared: All data is potentially shareable after unidentified individuals When: Access period starts 6 months after the results are published To whom: Researchers working in academic and scientific institutions Conditions: Students and researchers can use the data of this study. Where to obtain: Researchers can contact the study author via email at Drnegar.gheytassi@gmail.com to receive data and information. How to obtain: Request information and data to the author via email Drnegar.gheytassi@gmail.com Comments:

public Negar Gheytassi

Amir Al-Momenin Hospital, Next to the School of Medicine, Basij Square (Sardasht), Arak

Arak Iran (Islamic Republic of) 3848176941 +98 86 3417 3601 Drnegar.gheytassi@gmail.com Arak University of Medical Sciences scientific Negar.Gheytassi

Amir Al-Momenin Hospital, Next to the School of Medicine, Basij Square (Sardasht), Arak

Arak Iran (Islamic Republic of) 3848176941 +98 86 3417 3601 Drnegar.gheytassi@gmail.com Arak University of Medical Sciences Iran (Islamic Republic of) Age ≥ 15 years and less than 50 years outpatients Women with iron deficiency with ferritin less than 30 micrograms per liter No pregnancy No breastfeeding right now Absence of comorbidities (ckd, DM, IHD, etc.) Lack of known history of inflammatory bowel disease Lack of known history of celiac disease No known history or thalassemia No known hereditary bleeding disorder Do not take multivitamin and mineral supplements (35 mg or more of essential iron per day) in the 2 weeks prior to randomization. No allergy to oral iron Lack of intravenous iron therapy in the last 12 weeks Do not receive anticoagulants (eg warfarin, apixaban, debigatran, adoxaban, Riveroxban) Lack of creatinine clearance less than 30 ml per minute Lack of hemoglobin less than 80 g / l with active bleeding No chemotherapy planned for the next 12 weeks. No surgery is scheduled for the next 12 weeks. 15 years 50 years Female Intolerance or non-response to oral iron gluconate, sulfate or fumarate in the last 12 weeks Received frequent anemia treatments and are resistant to anemia treatment. Dissatisfaction to participate in the study or lack of cooperation and consent to continue treatment Treatment - Drugs Treatment - Drugs Intervention group: In one group of patients, 150-200 mg of elemental iron is given daily (in the form of ferrofort tablets of Abidi Pharmaceutical Company twice a day). Intervention group: In the second group, patients are treated every other daybetween 150-200 mg of elemental iron (in the form of ferrufort tablets of Abidi company twice a day every other day). Hemoglobin. Timepoint: The beginning of the study, two weeks and a month and a half after the intervention. Method of measurement: Using the device. Ferritin. Timepoint: At the beginning of the study and one and a half months after the intervention. Method of measurement: Using the device. Retic COUNT. Timepoint: First and two weeks after the intervention. Method of measurement: Using the device. Serum iron levels. Timepoint: At the beginning of the study and one and a half months after the intervention. Method of measurement: Using the device. TIBC. Timepoint: At the beginning of the study and one and a half months after the intervention. Method of measurement: Using the device. General clinical symptoms(weakness, fatigue, drowsiness, restlessness, anxiety, etc.). Timepoint: at the beginning and end of the study. Method of measurement: check list. Side effects during the study (nausea and vomiting, black stools / heartburn, etc.). Timepoint: during the study. Method of measurement: check list. Arak University of Medical Sciences Approved 2021-06-27 Ethics committee of Arak University of Medical Sciences University of Medical Sciences, Payambar Azam University Complex. Deputy of research and technology Arak Markazi Iran (Islamic Republic of)